Connect with us

Business

COVID-19 booster shots: Here’s what you should know about side effects – Global News

Published

 on


It’s been more than a year since Canada first started rolling out COVID-19 vaccine doses. Now, Canadians are rolling up their sleeves to get booster shots to combat the highly transmissible Omicron variant. But do boosters have the same side effects as the initial vaccine shots?

Canada’s National Advisory Committee on Immunization (NACI) recommends that booster shots of an mRNA vaccine – from Pfizer and Moderna – be offered to adults aged 18 and above at least six months after their second dose.

Read more:

COVID-19 vaccine and booster tracker: How many Canadians are vaccinated?

In updated guidance released on Dec. 3, NACI also said immunocompromised Canadians may receive a second booster, or fourth shot, at least six months after their last dose.

Side effects are common when it comes to vaccines and booster shots are no different.

“Side effects often tell us that our immune systems are actually working and are responding as they should to the vaccine,” said Dr. Samir Sinha, director of geriatrics at Sinai Health and University Health Network hospitals in Toronto.


Click to play video: 'Is the severity of a COVID-19 vaccine’s side effects an indicator of its effectiveness?'



2:04
Is the severity of a COVID-19 vaccine’s side effects an indicator of its effectiveness?


Is the severity of a COVID-19 vaccine’s side effects an indicator of its effectiveness? – Jun 30, 2021

Experts say while some people may experience a more intense reaction to the shots with headaches, body chills and fatigue, others just feel some soreness in the arm that was injected.

“The adverse effects of dose three should not differ all that much compared to dose two or previous injections,” said Dr. Ciriaco Picirillo, an immunologist and senior scientist at the Research Institute of the McGill University Health Centre (MUHC).

Clinical trial data shows that a booster dose of an mRNA COVID-19 vaccine has a favourable safety profile comparable to the second dose of the primary series, according to NACI.

A survey conducted in Israel showed that most people who received a third dose of Pfizer COVID-19 vaccine felt similar or fewer side effects than they did after receiving the second shot.

Pfizer’s booster shot has exactly the same formula and dosage (30 micrograms) as the initial two doses.

Read more:

Pfizer’s 3rd COVID-19 shot has similar side effects to 2nd, Israeli survey finds

According to clinical trial data submitted to the U.S. Food and Drug Administration (FDA) by Pfizer, pain at the injection site was the most common adverse reaction – reported by 83 per cent of recipients.

Fatigue was the second most frequent side effect (63.8 per cent), followed by headache (48.4 per cent), muscle or joint pain (39.1 per cent) and chills (29.1 per cent). The side effects were mostly mild to moderate, lasting roughly two days after receiving the booster shot.

“Of note, swollen lymph nodes in the underarm were observed more frequently following the booster dose than after the second dose of a two-dose primary series,” the FDA said.

No deaths or other adverse events of clinical interest – such as myocarditis, pericarditis, Bell’s Palsy, or appendicitis –  were reported following the booster dose.


Click to play video: 'COVID-19: CDC approves booster for ages 12-15 as it stands firm on isolation requirements'



2:17
COVID-19: CDC approves booster for ages 12-15 as it stands firm on isolation requirements


COVID-19: CDC approves booster for ages 12-15 as it stands firm on isolation requirements

Moderna’s booster is the same formula but half the original dose – 50 micrograms – is administered, except for immunocompromised individuals, long-term care residents and those aged 70 and above, who should receive the full dose of 100 micrograms, as indicated by NACI.

Adverse reactions reported in Moderna’s booster clinical trials included pain at the injection site, fatigue, headache, muscle pain, joint stiffness, chills, nausea/vomiting, axillary swelling/tenderness, fever, swelling at the injection site, redness at the injection site, and rash.

Anaphylaxis and other severe allergic reactions, myocarditis, pericarditis, and syncope (fainting) have also been reported outside of clinical trials, Moderna said.

Immune response

A more intense reaction following a booster is sign of a stronger immune response, said Sinha.

“Some people are reporting that they’ve experienced side effects for the first time or a more significant level of side effects with their booster dose than they did with their first or second dose,” he said.

Read more:

No side effects after your COVID-19 vaccine? Don’t worry, it’s probably still working

Pfizer’s booster is preferred for those aged 18 to 29 years due to the lower risk of myocarditis and pericarditis with this vaccine, according to NACI’s guidelines.

However, those aged 30 and up can get either Moderna or Pfizer.

Sinha said there is no concrete data to suggest that one brand of vaccine would elicit more side effects compared to the other.


Click to play video: 'COVID headlines including Omicron, booster shots and different dosages'



5:33
COVID headlines including Omicron, booster shots and different dosages


COVID headlines including Omicron, booster shots and different dosages – Dec 13, 2021

According to Picirillo, it’s not entirely clear why some people develop adverse reactions, either local or systemic, and others do not.

Age could be a contributing factor, with younger people having more effects than older individuals, Picirillo said.

“This is thought to relate to the more robust and more vigorous immune responses in the young, particularly in the first line of defence, termed innate immunity.”

Other factors including pre-existing conditions, genetics and environmental factors are likely at play, he added.

Read more:

Half of people offered Moderna COVID shot refuse it, Ontario Pharmacists Association says

Canada has approved the mixing of mRNA vaccines, which means a subsequent booster dose can be different than the primary vaccine series.

There is no evidence of increased adverse effects if Pfizer and Moderna are combined, Picirillo said.

“There is no difference in the number, type or frequency of adverse effects if one were to give combinations of prime boost.”

© 2022 Global News, a division of Corus Entertainment Inc.

Adblock test (Why?)



Source link

Continue Reading

Business

Bank of Canada prepares for a long fight against inflation – The Globe and Mail

Published

 on


Governor of the Bank of Canada Tiff Macklem at the Bank of Canada in Ottawa, on Dec. 15, 2021.Justin Tang/The Canadian Press

Canada is on the cusp of a series of rapid interest-rate hikes, with the central bank poised to start raising the cost of borrowing as early as next week, beginning a sustained push to bring high inflation back under control.

After nearly two years of extraordinarily low interest rates, the Bank of Canada has arrived at a pivot point. Consumer prices are rising at the fastest pace in three decades, straining the bank’s credibility as an inflation fighter. Meanwhile, there’s growing evidence that the economy is operating at or near full capacity and no longer needs emergency monetary-policy support.

The central bank’s governing council faces the biggest decision since Governor Tiff Macklem took charge in June, 2020: whether to pull the trigger next Wednesday and start the process of normalizing interest rates; or whether to hold off until March to provide additional stimulus through the Omicron wave of the pandemic.

Bank of Canada rate hikes are coming, but that doesn’t mean a recession will follow

Today’s inflation is a problem the Bank of Canada can’t tackle alone

The last time the central bank raised interest rates was in October, 2018. The coming rate-hike cycle, which will see the cost of borrowing rise steadily over the next two years, is needed to tamp down rising inflation expectations and to start building up an interest-rate buffer before the next downturn. But it will also test the strength of Canada’s economic recovery, as well as the vulnerability of heavily indebted households.

“Private-sector debt is something that the Bank of Canada has to keep an eye on, particularly because the rate hikes that we’ll do in the next two years could affect the rates that people pay in renewing mortgages in 2024 and 2025 that they may have taken out at very low interest rates,” Avery Shenfeld, chief economist at Canadian Imperial Bank of Commerce, said in an interview.

“And while we’ve put households to a [stress] test to ensure that they will be able to pay those higher rates, it will still put a big squeeze on their spending power,” he said.

Bank of Canada officials said in December that they did not expect to raise the policy rate – which has been held at 0.25 per cent since early in the pandemic – until April at the earliest. Since then, however, they have received a string of data releases showing the strength of the labour-market recovery, a record jump in home prices and a sharp rise in expected inflation and wage growth.

A central-bank survey of businesses, released Monday, found that two-thirds of respondents expect inflation to remain above 3 per cent for the next two years – a potent signal for policy makers. Meanwhile, 80 per cent said they intend to raise wages faster next year compared with last year to attract scarce labour. On Wednesday, Statistics Canada reported that the consumer price index rose 4.8 per cent in December, the fastest annual pace of growth since 1991.

This data pushed a number of analysts to revise their interest-rate forecasts. Economists at Bank of Nova Scotia, National Bank and Laurentian Bank pencilled in a rate hike for Jan. 26. Other private-sector economists expect a March liftoff, although most say a rate hike next week is possible.

Market pricing for overnight index swaps suggests an 83-per-cent chance that the bank moves next week, according to Refinitiv data.

“The bank basically has a free option [to raise rates next week],” National Bank rates strategist Taylor Schleich said. “The economy is screaming that we need interest-rate normalization, and now the banks and the markets are kind of allowing them to do it. So you may as well take it.”

Mr. Macklem has not spoken publicly since mid-December. But he used his last speech to tee up a possible shift in January, noting that inflation was “well above our target, and we are not comfortable with where we are” – strong language for a central banker.

The bank’s latest projection shows the rate of inflation falling to close to 2 per cent by the end of 2022, and bank officials believe that many of the supply chain problems that have been pushing up consumer prices will normalize over the coming year.

At the same time, Mr. Macklem and his team expressed concern in December that higher wage growth and rising inflation expectations could feed into “second-round” price pressures and become baked into higher inflation.

The Bank of Canada is not alone in manoeuvring into place for rate hikes. After spending much of last year arguing that high inflation would be relatively short-lived, central bankers in many advanced economies changed their tune in the final months of 2021. The most significant turn came from the U.S. Federal Reserve, which is dealing with the highest inflation of any advanced economy and strong wage growth.

At its December meeting, the Federal Open Market Committee decided to accelerate the end of its massive asset purchase program. Minutes from the meeting released in early January showed Fed officials expected to raise rates “sooner or at a faster pace than participants had earlier anticipated,” setting up a possible March rate hike.

This change in the Fed’s narrative spurred a sharp repricing in global markets. Fixed-income securities sold off in expectation of rate hikes. Equity markets stumbled, with notable declines in growth stocks that greatly benefit from ultralow interest rates when calculating future cash flows.

“The BoC probably does not look to the Fed for validation and they make decisions based on their policy frameworks and analysis,” Jason Daw, Royal Bank of Canada’s head of North America Rates Strategy, said in an e-mail. “But one area that a hawkish Fed makes it slightly easier for the BoC to raise rates is less appreciation pressure on the Canadian dollar than otherwise.”

It’s taken a long time for the Bank of Canada to get to the point where rate hikes are a possibility. It began shrinking its government bond-buying program, known as quantitative easing, in the fall of 2020, and ended the program in October. It is now in what it calls the “reinvestment” phase, where it’s only buying government bonds to replace maturing assets it already owns.

The central bank’s next move depends largely on whether it wants to wait until after the current COVID-19 lockdowns in Ontario and Quebec are lifted, said Mr. Shenfeld of CIBC. He added that the trajectory of rate hikes over the next few years matters more than whether the bank starts hiking in January or March.

“The exact timing of these rate hikes is important to people doing high-frequency trading. But not of that much importance to where the economy ends up a year or two down the road, which is what the Bank of Canada is really targeting,” he said.

Derek Burleton deputy chief economist at Toronto-Dominion Bank, said he expects the bank to bring its policy rate back up to around 2 per cent over the coming years, although policy makers could move haltingly.

“There may be a bit of probing, they may have to hike a few times, see how it plays out on the economy,” Mr. Burleton said.

“I think one of the questions, and this is more directed at central-bank tightening globally, is whether we go through periods of financial-market turbulence, and that could be a factor that could delay a steady tightening.”

Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening. Sign up today.

Adblock test (Why?)



Source link

Continue Reading

Business

Evive Nutrition recalling smoothie product because of cyanide poisoning risk – CP24 Toronto's Breaking News

Published

 on


OTTAWA — Evive Nutrition Inc. is recalling its Immunity Super Functional Smoothie because it contains raw elderberries that may cause cyanide poisoning.

The Canadian Food Inspection Agency says the recall of the product sold online was triggered by consumer complaints, noting there have been reported illnesses associated with the product.

The agency says raw elderberries naturally contain cyanogenic glycosdies, which can release cyanide after being eaten.

It says that while the body can process small amounts of cyanide, larger amounts can result in poisoning and could lead to death.

Symptoms of cyanide poisoning include weakness and confusion, anxiety, restlessness, headache, nausea, difficulty breathing and shortness of breath, loss of consciousness, seizures and cardiac arrest.

The agency says it is conducting a food safety investigation that may lead to the recall of other products.

This report by The Canadian Press was first published Jan. 22, 2022.

Adblock test (Why?)



Source link

Continue Reading

Business

COVID-19 antiviral treatment arrives in Nova Scotia – CBC.ca

Published

 on


Nova Scotia says 900 treatment packages of the COVID-19 antiviral drug have landed in the province, but plans for prescribing Paxlovid are still being finalized.

The Health and Wellness Department said it is working to make the supply available “as soon as possible,” and details about the distribution of Pfizer’s Paxlovid are still being worked out with stakeholders including Nova Scotia Health.

Earlier this week, Health Canada approved the oral antiviral treatment designed to help the body fight off the virus, reduce symptoms from an infection and shorten the period of illness.

Dr. Lisa Barrett, who treats COVID-19 patients and will prescribe the therapeutic once it starts rolling out, said a plan for distribution could take another few weeks.

But she said the first 900 treatment packages will help 900 people. The drug is taken twice a day for five days. 

Dr. Lisa Barrett is an infectious disease specialist based out of Dalhousie University in Halifax. (CBC)

It will be made available to the most vulnerable, including those who are not fully vaccinated for one reason or another and people over the age of 50 who have a risk factor such as being a transplant or cancer patient. 

“We’re hoping that it’s going to make a difference for the most vulnerable people,” said Barrett in an interview on Thursday.

“This is for people at the highest risk of disease and we don’t want them to have to shield anymore at home.”

Barrett noted the medication is designed to reduce hospitalization and death. The hope is that it will help alleviate pressures on the health-care system, she said.

Recognizing the limitations

She also said the fact that the drug is only trickling into the province at this point does not concern her because it was studied on unvaccinated people who were at high risk with the Delta variant. 

“It’s not clear yet if there is as much of a benefit to preventing hospitalization and death in people who are partly vaccinated, but not fully, against Omicron,” said Barrett.

“I want people to be aware we’re not completely devastated that we don’t have hundreds of thousands of doses of this because we think it’s helpful but not for the whole population.

“It’s good to recognize the limitations of the data and where we sit right now.”

Barrett said those in the vulnerable population group should be tested as soon as possible if they have symptoms and report any positive results to Public Health and their doctor.

Doctors will be able to refer their patients to receive the drug. Those referrals will be reviewed and the patient will be contacted about how to receive the treatment.

She said outbreaks in hospitals and long-term care homes will also be monitored as a way of identifying people at risk who may need the treatment. 

Recent approval of drug ‘great news’

On Monday, Canada’s Chief Public Health Officer Dr. Theresa Tam said Health Canada’s approval was “great news” because Paxlovid could drive down severe outcomes in the current wave and beyond.

Paxlovid combines a new drug developed by Pfizer called nirmatrelvir with an existing antiretroviral drug named ritonavir, a low-dose HIV drug that helps nirmatrelvir remain active in the body longer.

After months of clinical trials, Pfizer reported in November that Paxlovid reduced the risk of hospitalization or death by 89 per cent compared to a placebo in non-hospitalized high-risk adults with COVID-19.

MORE TOP STORIES

Adblock test (Why?)



Source link

Continue Reading

Trending